Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70.55 CHF | -0.42% | -0.70% | -3.02% |
Apr. 17 | Switzerland's Galenica Issues CHF100 Million Bond Due 2031 | MT |
Mar. 14 | GALENICA : FY23 one-offs shroud decent underlying profitability growth |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.75% | 3.86B | B | ||
+17.03% | 71.39B | C+ | ||
+2.82% | 25.1B | C+ | ||
-1.22% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
+17.12% | 4.31B | B+ | ||
-3.38% | 3.93B | B- | ||
+22.08% | 3.64B | C+ | ||
+7.96% | 3.29B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GALE Stock
- Ratings Galenica AG